Neuroblastoma (NB) has the highest incidence of all extracranial solid tumors in children and is highly lethal. This study aims to establish a prognostic model of NB with MYCN-related genes. We determined the gene expression profiles of 900 NB samples from the UCSC database and four Gene Expression Omnibus (GEO) data sets, and performed a comprehensive bioinformatics analysis and clinical sample verification. After univariate Cox regression, least absolute shrinkage and selection operator (Lasso), and multivariate Cox regression analyses, four (AKR1C1, CHD5, PDE4DIP, and PRKACB) genes were finally selected and used to construct a risk score prognostic model. In the UCSC data set, the high-risk group exhibited a significantly worse prognosis than the low-risk group. In addition, the nomogram, which includes prognostic markers and clinical factors, demonstrates high prognostic value. Finally, the differential expression of the four genes in the model was verified by quantitative real-time PCR in clinical tissues. These findings of MYCN-related genes provide a new and reliable prognostic model for NB related to MYCN.
Get full access to this article
View all access options for this article.
References
1.
BalachandranV.P., GonenM., SmithJ.J., and DeMatteoR.P. (2015). Nomograms in oncology: more than meets the eye. Lancet Oncol, 16, e173–e180.
2.
BellamyJ., SzemesM., MeleghZ., DallossoA., KollareddyM., CatchpooleD., et al. (2020). Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified neuroblastoma. Front Oncol, 10, 818.
3.
BosseK.R., and MarisJ.M. (2016). Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer, 122, 20–33.
4.
BrodeurG.M., PritchardJ., BertholdF., CarlsenN.L., CastelV., CastelberryR.P., et al. (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol, 11, 1466–1477.
5.
ChangW.M., ChangY.C., YangY.C., LinS.K., ChangP.M., and HsiaoM. (2019). AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway. J Exp Clin Cancer Res, 38, 245.
6.
ChenY., GaoY., TianY., and TianD.L. (2013). PRKACB is downregulated in non-small cell lung cancer and exogenous PRKACB inhibits proliferation and invasion of LTEP-A2 cells. Oncol Lett, 5, 1803–1808.
7.
CoughlanD., GianferanteM., LynchC.F., StevensJ.L., and HarlanL.C. (2017). Treatment and survival of childhood neuroblastoma: evidence from a population-based study in the United States. Pediatr Hematol Oncol, 34, 320–330.
8.
DeWanA.T., EganK.B., HellenbrandK., SorrentinoK., PizzoferratoN., WalshK.M., et al. (2012). Whole-exome sequencing of a pedigree segregating asthma. BMC Med Genet, 13, 95.
9.
DuZ., WuB., XiaQ., ZhaoY., LinL., CaiZ., et al. (2019). LCN2-interacting proteins and their expression patterns in brain tumors. Brain Res, 1720, 146304.
10.
EspiardS., KnapeM.J., BathonK., AssieG., Rizk-RabinM., FaillotS., et al. (2018). Activating PRKACB somatic mutation in cortisol-producing adenomas. JCI Insight, 3, e98296.
11.
FluckC.E., Meyer-BoniM., PandeyA.V., KempnaP., MillerW.L., SchoenleE.J., et al. (2011). Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet, 89, 201–218.
12.
GarciaI., MayolG., RodriguezE., SunolM., GershonT.R., RiosJ., et al. (2010). Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer, 9, 277.
13.
GravesC.A., JonesA., ReynoldsJ., StuartJ., PirisiL., BotrousP., et al. (2015). Neuroendocrine Merkel cell carcinoma is associated with mutations in key DNA repair, epigenetic and apoptosis pathways: a case-based study using targeted massively parallel sequencing. Neuroendocrinology, 101, 112–119.
14.
HuY., ZhangX., WangO., BiY., XingX., CuiM., et al. (2020). The genomic profile of parathyroid carcinoma based on whole-genome sequencing. Int J Cancer, 147, 2446.
15.
Huang daW., ShermanB.T., and LempickiR.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44–57.
16.
HuangM., and WeissW.A. (2013). Neuroblastoma and MYCN. Cold Spring Harb Perspect Med, 3, a014415.
17.
IrwinM.S., and ParkJ.R. (2015). Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am, 62, 225–256.
18.
KoyamaH., ZhuangT., LightJ.E., KollaV., HigashiM., McGradyP.W., et al. (2012). Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res, 18, 1588–1597.
19.
LaiJ., ZhouZ., TangX.J., GaoZ.B., ZhouJ., and ChenS.Q. (2016). A Tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma. Int J Mol Sci, 17, 739.
20.
LiuZ., and ThieleC.J. (2017). When LMO1 meets MYCN, neuroblastoma is metastatic. Cancer Cell, 32, 273–275.
21.
LoilomeW., JuntanaS., NamwatN., BhudhisawasdiV., PuapairojA., SripaB., et al. (2011). PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer, 129, 34–44.
22.
MaH., SongB., GuoS., LiG., and JinG. (2020). Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing. Cancer Biomark, 27, 389–397.
23.
MarisJ.M. (2010). Recent advances in neuroblastoma. N Engl J Med, 362, 2202–2211.
24.
MarisJ.M., HogartyM.D., BagatellR., and CohnS.L. (2007). Neuroblastoma. Lancet, 369, 2106–2120.
SausenM., LearyR.J., JonesS., WuJ., ReynoldsC.P., LiuX., et al. (2013). Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet, 45, 12–17.
30.
ShapshakP. (2012). Molecule of the month, PDE4DIP. Bioinformation, 8, 740–741.
31.
SkalheggB.S., and TaskenK. (2000). Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci, 5, D678–D693.
32.
SzklarczykD., FranceschiniA., WyderS., ForslundK., HellerD., Huerta-CepasJ., et al. (2015). STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 43, D447–D452.
33.
ThompsonP.M., GotohT., KokM., WhiteP.S., and BrodeurG.M. (2003). CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene, 22, 1002–1011.
34.
WangH., WangX., XuL., ZhangJ., and CaoH. (2020a). Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets. BMC Pediatr, 20, 314.
35.
WangY., WangB., ZhouH., ZhangX., QianX., and CuiJ. (2020b). MicroRNA-384 inhibits the progression of papillary thyroid cancer by targeting PRKACB. Biomed Res Int, 2020, 4983420.
36.
WardE., DeSantisC., RobbinsA., KohlerB., and JemalA. (2014). Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin, 64, 83–103.
37.
WengT.Y., WangC.Y., HungY.H., ChenW.C., ChenY.L., and LaiM.D. (2016). Differential expression pattern of THBS1 and THBS2 in lung cancer: clinical outcome and a systematic-analysis of microarray databases. PLoS One, 11, e0161007.
38.
WuD.M., WenX., HanX.R., WangS., WangY.J., ShenM., et al. (2018). Role of circular RNA DLEU2 in human acute myeloid leukemia. Mol Cell Biol, 38, e00259–18.
39.
YaoH., WuC., ChenY., GuoL., ChenW., PanY., et al. (2020a). Spectrum of gene mutations identified by targeted next-generation sequencing in Chinese leukemia patients. Mol Genet Genomic Med, 8, e1369.
40.
YaoX., HuW., ZhangJ., HuangC., ZhaoH., and YaoX. (2020b). Application of cAMP-dependent catalytic subunit beta (PRKACB) low expression in predicting worse overall survival: a potential therapeutic target for colorectal carcinoma. J Cancer, 11, 4841–4850.
41.
ZhaoS.F., WangS.G., ZhaoZ.Y., and LiW.L. (2019). AKR1C1–3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: database mining in malignancies. Oncol Lett, 18, 4515–4522.
42.
ZhongX., LiuY., LiuH., ZhangY., WangL., and ZhangH. (2018). Identification of potential prognostic genes for neuroblastoma. Front Genet, 9, 589.
43.
ZhuH., ChangL.L., YanF.J., HuY., ZengC.M., ZhouT.Y., et al. (2018). AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer. Theranostics, 8, 676–692.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
